phase

Rwanda Celebrates Completion of Smart Education Project and DigiTruck Launch

KIGALI, Rwanda, Oct. 6, 2025 /PRNewswire/ -- Huawei and Rwanda's Ministry of Education announced the completion of the first phase of…

2 months ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

October 05, 2025 09:00 ET  | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…

2 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…

3 months ago

FIA: After announcing her candidacy, Laura Villars reaches out to all member clubs

GENEVA, Sept. 24, 2025 /PRNewswire/ -- Just days after officially announcing her candidacy for the FIA Presidency, Swiss racing driver and entrepreneur…

3 months ago

LANZAJET AND KAZMUNAYGAS (KMG) ANNOUNCE KAZAKHSTAN’S FIRST SUSTAINABLE AVIATION FUEL PROJECT PASSES MAJOR MILESTONE AND ADVANCES TO ENGINEERING AND DESIGN PHASE

As part of New York Climate Week, LanzaJet's CEO addressed the President of the Republic of Kazakhstan and met with…

3 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…

3 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

September 20, 2025 11:00 ET  | Source: C4 Therapeutics, Inc. Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response…

3 months ago

Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants…

3 months ago

Milano Cortina 2026 ramps up excitement as Italy enters final delivery phase

17 September 2025 - With just 70 days to go until the Olympic flame is lit in Olympia, Greece, the International…

3 months ago

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…

3 months ago